ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)
Clinical trial NCT05601752 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05601752
- Sponsor
- USWM CT, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-26
- Primary completion
- 2026-08-12
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.